Biocon Shares Gain Amid High Volume, Up by 0.47%

During today's session, Biocon experienced a notable surge in trading volume, resulting in a 0.47% increase in its share price. The stock is currently trading at Rs 350.85. This high volume activity, coupled with the price movement, has drawn attention from investors and market analysts.

Biocon stock's performance is particularly significant as it is a constituent of key indices including the NIFTY MIDCAP 150 and Nifty LargeMidcap 250, making its movements relevant to a wide array of market participants.

Financial Performance Overview

An examination of Biocon's recent consolidated financial results offers additional perspective on the stock's current dynamics.

Quarterly Performance Highlights

For the quarter ending March 2025, Biocon's consolidated financial highlights include:

• Revenue: Rs 4,417.00 Cr, compared to Rs 3,821.40 Cr in December 2024.


• Net Profit: Rs 459.40 Cr, a substantial rise from Rs 81.10 Cr in the previous quarter.


• EPS: Rs 2.88, up from Rs 0.21 in December 2024.

Annual Performance Summary

Over the past five years, Biocon has consistently grown its consolidated annual financials:

• Revenue: Increased from Rs 7,105.80 Cr in 2021 to Rs 15,261.70 Cr in 2025.


• Net Profit: Increased from Rs 925.40 Cr in 2021 to Rs 1,429.40 Cr in 2025.


• EPS: Increased from Rs 6.24 in 2021 to Rs 8.46 in 2025.

Key Financial Ratios

Analysis of Biocon's key financial ratios provides deeper insights into its financial stability and performance:

• Return on Equity (ROE): 4.68% as of March 2025.


• Debt to Equity Ratio: 0.82 as of March 2025.


• P/E Ratio: 40.39 as of March 2025.


• P/B Ratio: 1.89 as of March 2025.

Cash Flow Analysis

An analysis of Biocon's cash flow from operating activities reflects its operational effectiveness:

• Cash Flow from Operating Activities: Rs 4,061 Cr in March 2025, compared to Rs 2,953 Cr in March 2024.

Balance Sheet Overview

Key observations from Biocon's balance sheet include:

• Share Capital: Maintained consistently at Rs 600 Cr over the past five years.


• Reserves & Surplus: Grew from Rs 6,931 Cr in 2021 to Rs 21,043 Cr in 2025.


• Total Assets: Increased from Rs 18,522 Cr in 2021 to Rs 58,797 Cr in 2025.

With the stock currently priced at Rs 350.85, Biocon's recent financial performance, high trading volume, and presence in major market indices collectively indicate sustained investor interest and activity.